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Abstract
Background:  In recent years, numerous studies have investigated somatic mutations in
mitochondrial DNA in various tumours. The observed high mutation rates might reflect
mitochondrial deregulation; consequently, mutation analyses could be clinically relevant. The
purpose of this study was to determine if mutations in the mitochondrial D-loop region and/or the
level of mitochondrial gene expression could influence the clinical course of human ovarian
carcinomas.
Methods: We sequenced a 1320-base-pair DNA fragment of the mitochondrial genome (position
16,000-750) in 54 cancer samples and in 44 corresponding germline control samples. In addition,
six transcripts (MT-ATP6, MT-CO1, MT-CYB, MT-ND1, MT-ND6, and MT-RNR1) were quantified in
62 cancer tissues by real-time RT-PCR.
Results:  Somatic mutations in the D-loop sequence were found in 57% of ovarian cancers.
Univariate analysis showed no association between mitochondrial DNA mutation status or
mitochondrial gene expression and any of the examined clinicopathologic parameters. A
multivariate logistic regression model revealed that the expression of the mitochondrial gene RNR1
might be used as a predictor of tumour sensitivity to chemotherapy.
Conclusion: In contrast to many previously published papers, our study indicates rather limited
clinical relevance of mitochondrial molecular analyses in ovarian carcinomas. These discrepancies
in the clinical utility of mitochondrial molecular tests in ovarian cancer require additional large,
well-designed validation studies.
Background
Mitochondria are most notably involved in ATP produc-
tion but also contribute to thermogenesis, free radical pro-
duction, calcium homeostasis, and apoptosis [1]. ATP
production is required for most cellular functions, and
cellular energy requirements are largely met by the mito-
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chondrial oxidative phosphorylation system. Mammalian
mitochondria contain ~1000 proteins [2] but only 13 of
them are encoded by the mitochondrial genome [3].
Other mitochondrial proteins are encoded by nuclear
DNA, synthesized in the cytoplasm, and imported by the
mitochondria.
Although several mitochondrial proteins [4,5] form the
nucleoid, which is a mitochondrial DNA-protein com-
plex, their protective effects against mutagenesis are much
less strong than those in the nuclear genome [6]. In addi-
tion, the high rate of mitochondrial DNA (mtDNA) muta-
tion, which is several times higher than the rate for
nuclear DNA [6-8], is likely explained by the production
of reactive oxygen species by the mitochondrial oxidative
phosphorylation system [8-10]. Increased accumulation
of mtDNA somatic mutations has been reported in aging
tissues such as brain, skeletal muscle, and fibroblasts
[7,11,12] and in many pathological conditions including
neurologic, metabolic, and age-related disorders. These
alterations are especially prevalent in preneoplastic
lesions and in human cancers, including breast cancer,
ovarian cancer, colorectal cancer, gastric cancer, hepatic
cancer, esophageal cancer, prostate cancer, and thyroid
cancer [13-31]. Most studies on mtDNA mutation have
focused on sequencing of the D-loop region.
Somatic mutations can occur throughout the mitochon-
drial genome sequence [14,17,26,28,32-34], but two
hypervariable regions (HV1 and HV2) of the D-loop rep-
resent mutational hot spots [17,35]. The mononucleotide
repeat between nt 303 and 309 is the most unstable mic-
rosatellite sequence within the non-coding D-loop region.
This microsatellite sequence forms a persistent DNA-RNA
hybrid that initiates replication of the mtDNA heavy
strand [36]. Mutations within the C-stretch region from nt
303 to 309 may alter the regulation of mtDNA replication
and, consequently, the mtDNA content in tumours.
Whereas an increased number of mitochondria were
found in thyroid cancer tissue [37], a decreased copy
number of mtDNA was described in hepatocellular carci-
noma harboring D-loop mutations [38].
The mitochondrial circular DNA is almost completely and
symmetrically transcribed from its heavy and light
strands, and the resulting polycistronic RNA is processed
by endonucleolytic cleavage [39]. Mitochondrial gene
expression parallels changes in the copy number of mito-
chondrial DNA [40,41]. The replication origin for the
leading strand, the heavy- and light-strand promoters,
their mitochondrial transcription factor A (mTFA) bind-
ing sites and the three conserved sequence blocks [3,42]
are located within the displacement-loop (D-loop) of the
mitochondrial genome. The mtTFA enhances mitochon-
drial DNA transcription in a promoter-specific fashion, in
the presence of mitochondrial RNA polymerase and tran-
scription factor B [43]. It seems that mtTFA is also crucial
for replication [44] and for maintaining of mitochondrial
DNA [5].
The D-loop is a control site for expression of the mito-
chondrial genome. Mutations which are located in regula-
tory elements of the D-loop region have been associated
with the reduction in the ND6 expression and in the
mtDNA copy number [42]. It seems therefore that func-
tional location of some mutations within the control
region may alter the rate of mtDNA transcription and rep-
lication.
Mitochondria are central executors of apoptosis, which is
the main mechanism of tumor cell loss during chemo-
therapy. MtDNA may determine the cellular response to
some anticancer agents [45-47], and mutations in the D-
loop region have been correlated with resistance to FU-
based chemotherapy in colon cancer patients [48]. As an
independent prognostic factor in cancer patients, somatic
mutation of mtDNA might also serve as a potential
tumour marker [48].
Thus, many studies have proposed that mtDNA muta-
tions might serve as both biomarkers of carcinogenesis
and as predictive factors for the disease course. Our study
analyzed the DNA sequence of the D-loop region and the
expression of mitochondrial genes in ovarian cancer sam-
ples, and the association of molecular findings with clini-
cal endpoints was evaluated. No significant relationship
was found between mitochondrial alterations and clinical
characteristics of the studied patients.
Methods
Patients
Ovarian cancer specimens were obtained from patients
with FIGO IIC-IV disease during the initial surgical treat-
ment prior to chemotherapy [49]. One to 10 tumour's
fragments, depending on the tumour size, were snap fro-
zen and stored at -72°C until use. Then, histological eval-
uation of the group of 106 tumours and over 300 of their
tumour fragments was performed to control their relative
content of non-tumour tissue. Several series of cryostat
sections were prepared from different parts of each
tumour's fragment. Upper and lower sections from each
cryosection collection were evaluated by the pathologist
(JK), and the rest of the tissue material was used in the
study if it contained up to 5% fraction of stromal cells.
Altogether, we selected 62 cancers which were represented
by at least one cryosection collection containing ≥ 95%
cancer cells. Forty-four matched peripheral blood samples
served as germline controls. The study protocol was
approved by the local Bioethical Committee, and allBMC Cancer 2008, 8:292 http://www.biomedcentral.com/1471-2407/8/292
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patients signed an informed consent form before inclu-
sion.
The tumours were classified histologically (JK) according
to the criteria of the World Health Organization [50] and
were graded on a 4-grade scale according to the Broders'
criteria [51]. There were 59 serous carcinomas and 3 can-
cers of other types; 5 tumours showed moderate differen-
tiation (G2), 42 were poorly differentiated (G3), and 15
were mostly or completely undifferentiated (G4).
Twenty-seven patients were treated with platinum-cyclo-
phosphamide therapy, and 35 patients were treated with
taxane-platinum therapy. The criteria for evaluation of
clinical endpoints were given previously [52]. In particu-
lar, platinum sensitivity was defined as complete remis-
sion, with disease-free survival ≥ 180 days. Other tumours
were described as resistant to chemotherapy. The TP53
gene status of the tumours was analyzed previously [52].
Sequencing of mtDNA D-loop
Standard molecular biology techniques were used. Total
genomic DNA from tissue samples was purified with the
DNeasy Tissue Kit (Qiagen GmbH, Hilden, Germany).
The D-loop sequence of mtDNA was PCR amplified with
primers D1F/D3R (Table 1). PCR products were
sequenced in two directions by fluorescent dideoxyse-
quencing on an ABI Prism 3100 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA) with primers
listed in Table 1.
Real-time RT-PCR analysis
Specific RNA concentrations were determined by real-
time reverse transcriptase (RT)-PCR. Total tissue RNA was
isolated with the RNeasy Mini Kit and QIAshredder col-
umns (Qiagen GmbH, Hilden, Germany). Reverse tran-
scription was performed with the SuperScript II Reverse
Transcriptase (Invitrogen Co., Carlsbad, CA) reagent set
according to the manufacturer's instructions. Quantitative
Table 1: Sequences of oligonucleotide primers used in real-time PCR and sequencing reactions
Primer pairs used in real-time PCR reactions
Gene Primer sequence
ACTB Forward: 5'-TGCGTTACACCCTTTCTTGACA
Reverse: 5'-GCAAGGGACTTCCTGTAACAATG
GAPDH Forward: 5'-GAAGGTGAAGGTCGGAGTC
Reverse: 5'-GAAGATGGTGATGGGATTTC
MT-ATP6 Forward: 5'-TAGCCATACACAACACTAAAGGACGA
Reverse: 5'-GGGCATTTTTAATCTTAGAGCGAAA
MT-CO1 Forward: 5'-GACGTAGACACACGAGCATATTTCA
Reverse: 5'-AGGACATAGTGGAAGTGAGCTACAAC
MT-CYB Forward: 5'-ATCACTCGAGACGTAAATTATGGCT
Reverse: 5'-TGAACTAGGTCTGTCCCAATGTATG
MT-ND1 Forward: 5'-CCACCTCTAGCCTAGCCGTTTA
Reverse: 5'-GGGTCATGATGGCAGGAGTAAT
MT-ND6 Forward: 5'-CAAACAATGTTCAACCAGTAACCACTAC
Reverse: 5'-ATATACTACAGCGATGGCTATTGAGGA
MT-RNR1 Forward: 5'-TAGAGGAGCCTGTTCTGTAATCGAT
Reverse: 5'-CGACCCTTAAGTTTCATAAGGGCTA
UBC Forward: 5'-ATTTGGGTCGCGGTTCTTG
Reverse: 5'-TGCCTTGACATTCTCGATGGT
Primers used in sequencing reactions
Primer name Primer sequence
D1F A Forward: 5'-AATGGGCCTGTCCTTGTAG
D2F Forward: 5'-CGACATCTGGTTCCTACTTC
D3F Forward: 5'-CGCTTCTGGCCACAGCAC
L16112F Forward: 5'-CACCATGAATATTGTACGGT
D2R Reverse: 5'-GGGTTTGGTTGGTTCGGG
D3R A Reverse: 5'-GGTGTGGCTAGGCTAAGC
DLP4R Reverse: 5'-GTGGAAAGTGGCTGTGCAG
H16220R Reverse: 5'-TTGATTGCTGTACTTGCTTGTAAG
H16540R Reverse: 5'-GTGGGCTATTTAGGCTTTATGACCCTG
A Primers used for PCR amplification of sequenced mtDNA fragment.BMC Cancer 2008, 8:292 http://www.biomedcentral.com/1471-2407/8/292
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evaluation of mRNA was performed on an ABI Prism
7000 Sequence Detection System with a 25-μl reaction
mixture containing 12.5 μl 2× SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA), 5 μl cDNA,
and 50 nM primers. Oligonucleotide primers for the ana-
lyzed gene transcripts were designed with Primer Express
Software (Applied Biosystems, Foster City, CA) and are
listed in Table 1. For each run, standard curves were gen-
erated for a primer set by serial dilution of pooled cDNA
to counterbalance variations in PCR reaction efficiency.
Melting curves were generated after each reaction to verify
the melting temperature of the amplicon. In addition, the
purity of the RT-PCR product was verified by agarose gel
electrophoresis. To normalize nonspecific variations in
real-time PCR, the normalization factor was calculated as
the geometric mean of RNA concentrations of three con-
trol genes, glyceraldehyde-3-phosphate dehydrogenase, ubiqui-
tin C, and β-actin.
Statistical analysis
All continuous variable data were presented as median
and range and were analyzed with the Mann-Whitney U
test. The two-tailed Fisher's exact test was used to deter-
mine the relationships between categorical variables and
D-loop mutations. Tumour response to chemotherapy
was evaluated with the multivariate logistic regression
model. Factors were selected with the backward selection
technique, in which factors not significant at 0.1 were
removed stepwise from the model. Initial multivariate
models included the following variables: age of patient,
FIGO stage, residual tumour size, grade, TP53 mutation,
first-line therapy, haplogroup, D-loop somatic mutations,
and expression of RNR1,  ATP6,  CO1,  CYB,  ND1, and
ND6. Gene expression variables and age of patients were
categorized by the median values.
P values of less than 0.05 were considered significant. Cal-
culations were performed with the STATA 6.0 program
(Stata Corporation 1999, College Station, TX).
Results
Variability of mtDNA in ovarian cancer
We sequenced a 1320-base-pair DNA fragment of the mt
genome (positions 16000-750), which included the con-
trol region with the D-loop (positions 16024-576), in 54
cancer tissue samples and in 44 corresponding germline
control samples. The complete sequencing results are
available at http://gastrolab.coi.waw.pl. The obtained
sequences were compared with the revised human mito-
chondrial Cambridge reference sequence deposited in
GenBank (accession number AC_000021). Most of the
sequence variations were identified as neutral polymor-
phisms of human mtDNA because they were found in
both tumour and control DNA samples.
The D-loop sequences from the 54 ovarian cancer samples
were used to assign patients to specific haplogroups,
according to the method described by Finnilla et al. and
Torroni et al. [53,54]: H (n = 27), U (n = 7), T (n = 6), J (n
= 3), K (n = 3), unspecified (n = 3), I (n = 2), W (n = 2),
and V (n  = 1). The frequency of haplogroup variants
found in the ovarian cancer patients was similar to that of
the Polish population [55] (not shown), which supports
the accuracy of the sequencing data obtained in this study
[56]. Because most haplogroups were represented by only
a few patients, to simplify further analyses, we divided
patients into two haplogroups: H and all others. No sig-
nificant association of tumour mutations with either of
these two groups was found (Table 2).
The sequencing results from 44 paired tumour and match-
ing blood samples were used to search for differences that
distinguished tumour mtDNA from blood mtDNA.
Thirty-three somatic mutations were found in 25 of 44
(57%) ovarian cancer samples. The most frequent altera-
tions were changes in length of homopolymeric C-tracts,
which were found in 18 paired samples (positions
303–315, n = 15; positions 16184–16193, n = 3). The
remaining 15 somatic mutations were substitutions
detected in 11 specimens. Whereas the majority of length
changes were heteroplasmic (15 of 18), most of the sub-
stitutions were homoplasmic (13 of 15).
Four of the substitutions, m.565A>G, m.586G>A, and
heteroplasmic m.567A>C and m.16034G>A, were not
recorded in the mtDBase database http://www.gen
pat.uu.se/mtDB/index.html[57]. However, the
m.586G>A mutation was found previously in colonic
crypts, as recorded in the MITOMAP database http://
www.mitomap.org/cgi-bin/tbl14gen.pl[58]. Five other
mutations were relatively rare: m.16193C>T (13/1854),
m.16218C>T (9/1858), m.16390G>A (62/1805),
m.16391G>A (17/1850), and m.16465C>T (4/1863). In
parentheses are the numbers of records in the mtDBase
database with/without this variant. Interestingly, in two
cases the blood samples had an uncommon mtDNA
sequence that was reversed by mutation to a frequent var-
iant in tumours: m.16248T>C (1865/2) and m.16292T>C
(1801/64). Finally, two mutations, m.195C>T (280/
1574) and m.16519C>T, found in 3 samples (1115/752)
occurred in positions that are variable in mitochondrial
DNA, and both forms are common in the human popula-
tion.
Association of D-loop somatic mutations and patient 
clinicopathologic characteristics
Table 2 summarizes the presence of D-loop mutations
according to clinicopathologic data, as evaluated by the
two-tailed Fisher's exact test. No significant associations
were found between the presence of mtDNA mutationsBMC Cancer 2008, 8:292 http://www.biomedcentral.com/1471-2407/8/292
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and the histopathological tumour grading, presence of
residual tumour, or mutation of TP53. No differences in
tumour mutation frequencies were found between two
groups of patients who were divided with respect to age
below or above the median. No relation between muta-
tional variability of this mtDNA region and response to
chemotherapy was proven. A multivariate logistic regres-
sion model that contained haplogroup and mutation
indicators also revealed no association of D-loop somatic
mutations with any of the analyzed clinicopathologic
parameters (data not shown).
Association of mitochondrial gene expression with 
response to chemotherapy
Total RNA was isolated, and six transcripts that encoded
polypeptides (MT-ATP6, MT-CO1, MT-CYB, MT-ND1,
and MT-ND6) and ribosomal 12S RNA (MT-RNR1) were
quantified by real-time RT-PCR. Because it was not possi-
ble to obtain sample pairs of ovarian carcinoma and cor-
responding normal tissue, gene expression was studied
only in 62 tumour samples. Analysis of the results with
the Mann-Whitney U test revealed that mutations in the
D-loop did not influence the expression of mitochondrial
genes (Fig. 1A). Furthermore, the expression of all ana-
lyzed mitochondrial genes was equal in responders and
non-responders to the therapy (Fig. 1B). However, when
the probability of sensitivity to chemotherapy was evalu-
Table 2: Results of statistical analyses of associations between D-loop mtDNA mutation and clinicopathologic parameters in 44 
ovarian cancer patients
Parameter Number of patients Number of patients with mutated 
tumour
Number of patients with non-mutated 
tumour
P-value
Overall 44 25 19
Age (median = 53)
> 53 19 13 7
≤ 53 24 12 12 0.3175
Grading
G2 + G3 31 20 11
G4 12 5 7 0.3014
FIGO stage
II-IIIB 10 5 5
IIIC, IV 34 20 14 0.7233
Residual tumour
> 2 cm 14 9 5
0–2 cm 29 16 14 0.534
TP53 mutation
Yes 23 14 9
No 20 11 10 0.7613
Response to chemotherapy
Platinum-based
Yes 10 5 5
No 9 5 4 1
Taxane/platinum-based
Yes 12 9 3
No 12 6 7 0.2262
Both types of therapy
Yes 22 14 8
No 21 11 11 0.5434
Haplogroups
H2 2 1 4 9
Others 21 11 10 0.7613
Statistical significance was analyzed with the two-tailed Fisher's exact test.BMC Cancer 2008, 8:292 http://www.biomedcentral.com/1471-2407/8/292
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ated with a multivariate logistic regression model, both
clinical parameters (age, FIGO stage, and grade) and the
expression of RNR1 appeared to be predictors of platinum
sensitivity (Table 3).
Discussion
In the present study, somatic mutations in the D-loop
region of mtDNA were found in > 50% of ovarian cancer
tissue samples, and most samples harbored a single muta-
tion. These results are consistent with previous reports
that described somatic D-loop mutations in 20–78% of
human cancers [6,59,60]. However, the presence of these
somatic mutations did not correlate with clinicopatho-
logic parameters.
Views on the importance of mtDNA mutational variabil-
ity in tumours vary from complete disbelief [61] through
cautious acceptance of at least some data [62] to optimis-
Relative mRNA expression of selected genes in specimens from patients with ovarian carcinomas Figure 1
Relative mRNA expression of selected genes in specimens from patients with ovarian carcinomas. A. – samples 
divided according to mutational status of the mtDNA D-loop (W – wild type, n = 19; M – mutated, n = 25). B. – samples 
divided according to response to chemotherapy (S – sensitive, n = 32; R – resistant, n = 30). Data are presented as mRNA 
expression levels for selected genes normalized to the geometric mean of the RNA concentrations of three control genes, glyc-
eraldehyde-3-phosphate dehydrogenase, ubiquitin C, and β-actin. The boxes show the upper and the lower quartiles; the median 
values are shown as a horizontal line in each box; the whiskers represent minimum and maximum of the data values. Data were 
analyzed with the Mann-Whitney U test.
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Table 3: Probability of sensitivity to chemotherapy in the group 
of 44 ovarian carcinomas as evaluated by the multivariate 
logistic regression model
OR 95% CI for OR P-value
Age
≥ 53 vs. < 53 0.097 [0.02, 0.41] 0.002
Grade
4 vs. 3, 2 0.15 [0.03, 0.76] 0.022
FIGO stage
IIIC, IV vs. II, IIIB 0.099 [0.01, 0.64] 0.015
RNR1 expression
> 1 vs. < 1 0.21 [0.05, 0.86] 0.031
Abbreviations: OR – odds ratio; CI – confidence interval.BMC Cancer 2008, 8:292 http://www.biomedcentral.com/1471-2407/8/292
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tic belief that mitochondrial studies in cancer patients
might be employed to search for reliable disease markers
[6]. Two major problems exist in several published stud-
ies. First, most of these studies analyzed relatively small
groups. Second, some studies compared the sequences
obtained from tumours with the Cambridge reference
sequence instead of with corresponding germline con-
trols, which yields obvious differences (e.g., Aikhionbare
et al., 2007 [14]).
Brandon et al. [15] compiled an extensive list of mtDNA
mutations identified in tumours and concluded that
many of them are sequence polymorphisms found in
databases. This was true for 85% of the mitochondrial
control region mutations that were analyzed. Such muta-
tions have occurred during human evolution and can be
used for categorization according to mitochondrial haplo-
groups. We did not detect any significant association of a
specific haplogroup with tumour occurrence. Thus far,
convincing data have been found only by Booker et al.
[63] for haplogroup U association with prostate and renal
cancer. Although an association between haplogroups
and predisposition to ovarian cancer could not be found,
it should be noted that proving any association of mito-
chondrial haplogroups with a disease is extremely diffi-
cult. To obtain convincing evidence, very large patient and
control groups are required, which are not available for
most studies [64].
The unstable C-tract is located in the hypervariable seg-
ment II region of the D-loop of mtDNA, and length varia-
tions of this mononucleotide sequence are regarded as
common polymorphisms. All sequence changes in the C-
tract that were found in our study were insertions or dele-
tions of one or two base pairs. Interestingly, although the
unstable C-stretch is a hotspot for somatic mutation in
ovarian cancers, as well as in other human cancers such as
colorectal, lung, and liver [19,21,48,60,65,66], Sanchez-
Cespedes et al. did not detect somatic insertions at the C-
stretch sequence in ovarian and prostate cancers [66].
Most of the mutations identified in the present study are
of the type described by Brandon et al. [15], i.e., changes
in sites known to be polymorphic in the population.
However, some of the mutations identified in the present
study are very rare in the population databases
(m.16193C>T, m.16218C>T, m.16391G>A,
m.16465C>T, m.586G>A) or were not found in any data-
base (m.565A>G, m.A567A>C, m.16034G>A). The scar-
city of these mutations does not prove that they are
cancer-specific, but they are at least uncommon. None of
these mutations were found in ovarian cancers by Liu et
al. [67], who found mutations in 20% (3 of 15) of paired
tumour and normal tissue samples.
The functional significance of mtDNA mutations and
their potential role in tumour development are still uncer-
tain. In particular, it has not been established whether
somatic mutations of mtDNA are involved in molecular
mechanisms of tumour development or whether these
mutations are merely associated with the tumourigenic
process but lack a causative role.
Conclusion
The present study showed for the first time that, in addi-
tion to clinical parameters, the expression of the mito-
chondrial gene RNR1  in tumour tissue might predict
sensitivity of ovarian carcinomas to chemotherapy. How-
ever, the overall clinical relevance of mitochondrial
molecular analyses in ovarian carcinomas seems to be
rather limited. As pointed out by Salas et al. [61], the
improper analysis and interpretation of mtDNA sequence
data may lead to misinterpretations that, in turn, can be
further duplicated from the published reports. In contrast
to many previously published papers, our study indicates
that the usefulness of estimation of the D-loop mtDNA
sequence variability as a clinical cancer marker is ques-
tionable. Thus, the acceptance of any diagnostic mito-
chondrial molecular test for clinical practice requires
additional large, well-designed validation studies.
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